Selected article for: "activity models and machine learning"

Author: Tinkov, O. V.; Grigorev, V. Yu.; Grigoreva, L. D.
Title: Virtual Screening and Molecular Design of Potential SARS-COV-2 Inhibitors
  • Cord-id: mg112iyx
  • Document date: 2021_6_16
  • ID: mg112iyx
    Snippet: According to recent studies, the main M(pro) protease of the SARS-CoV-2 virus, which is the most important target in the development of promising drugs for the treatment of COVID-19, is evolutionarily conservative and has not undergone significant changes compared with the main M(pro) protease of the SARS-CoV virus. Many researchers note the similarity between the binding sites of the main M(pro) protease of SARS-CoV and SARS-CoV-2 viruses; thus, with the spreading epidemic, further studies on i
    Document: According to recent studies, the main M(pro) protease of the SARS-CoV-2 virus, which is the most important target in the development of promising drugs for the treatment of COVID-19, is evolutionarily conservative and has not undergone significant changes compared with the main M(pro) protease of the SARS-CoV virus. Many researchers note the similarity between the binding sites of the main M(pro) protease of SARS-CoV and SARS-CoV-2 viruses; thus, with the spreading epidemic, further studies on inhibitors of the main M(pro) protease of the SARS-CoV virus to fight COVID-19 seems logical. In the course of the study, satisfactory QSAR models are built using simplex, fractal, and HYBOT descriptors; the Partial Least Squares (PLS), Random Forest (RF), Support Vectors, Gradient Boosting (GBM) methods; and the OCHEM Internet platform (https://ochem.eu), in which different types of molecular descriptors and machine learning methods are implemented. The structural interpretation, which allowed us to identify molecular fragments that increase and decrease the activity of SARS-CoV inhibitors, is performed for the obtained models. The results of the structural interpretation are used for the rational molecular design of potential SARS-CoV-2 inhibitors. The resulting QSAR models are used for the virtual screening of 2087 FDA-approved drugs.

    Search related documents:
    Co phrase search for related documents
    • acceptor donor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • accuracy assessment and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • accuracy assessment and acute toxicity: 1
    • active center and acute respiratory syndrome: 1, 2, 3, 4
    • active compounds and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active compounds and acute respiratory syndrome outbreak: 1, 2, 3, 4, 5
    • active compounds and acute toxicity: 1, 2
    • active inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • active substance and acute respiratory syndrome: 1, 2
    • active substance and acute toxicity: 1
    • activity change and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • activity increase and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity increase and acute respiratory syndrome outbreak: 1, 2
    • activity increase and acute toxicity: 1
    • activity reduce and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • activity structure and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity structure and acute respiratory syndrome outbreak: 1, 2, 3
    • activity structure and acute toxicity: 1, 2, 3, 4
    • activity structure and ad applicability domain: 1